University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia
Full Professor of Clinical Biochemistry, PI in genetics of complex disorders
Full professor of Clinical Biochemistry, coordinator of PhD program of Clinical Biochemistry at University of Ljubljana and principal coordinator of the CEEPUS CIII-SI-0611 network of student exchange program. Her research is focused on genetic backgrounds of complex diseases like osteoporosis, osteoarthritis, insulin resistance, obesity (metabolic syndrome), etc. After genotype-phenotype association studies her group continued to functional evaluation of genetic variations using primary and mesenchymal stem cell models. She is the member of four international consortiums and is the partner in the Interreg IT-SLO EU-project ARTE (2017-2020). Her bibliography consists of over 120 scientific papers (h-index=21) and is the member of editorial boards of five international scientific journals. For her contribution to development of laboratory medicine profession in Slovenia she received the Recognition from SACCLM in 2016.
Member: SACCLM, EFLM, ECTS, ESPT
Thermo Fisher Scientific
Associate Director, Business Development Genetic Sciences Division
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer.
In my role as Associate Director business development within the Genetic Science Division, I am focusing on the development and introduction of novel solutions for the Healthcare market. This includes solutions for pharmacogenomics testing, infectious disease testing as well as novel screening tools for the oncology market. I am ESPT board member, representing the ESPT Corporate members.
Member: European Society of Pharmacogenomics and Personalised Therapy
Dr. Adrián LLerena Ph.D. is the Director of the Clinical Research Center in the University Hospital in Badajoz Spain. He is also professor of Pharmacology and Clinical Pharmacology in the Medical School of the University of Extremadura, between 1989-1993 he did his post doc at Karolinska Institute Sweden focusing on Clinical Pharmacogenetics. His teaching experience is of more than 20 years in Spain and of about 9 years in Portugal. He has supervised more than 10 Ph.D. theses so far. He has also been an invited professor in different Universities in USA such as University of California at Los Angeles 2004 Mount Sinai Medical School at NY 2005 and Miller Medical School at Miami 2006 and in Latin America such as UNAM in Mexico San Marcos in Peru, Chile UFMG Brasil, Australian National University in Camberra etc. He has published more than 150 peer reviewed papers and book chapters. He is also coordinating the Iberoamerican network of Pharmacogenetics since 2006. He served in different Scietific societies as IberoAmerican Society of Pharmacogenomics. He has been principal investigator in more than 30 national and european research projects. He has also served as reviewer in all journals related to clinical pharmacology and mainly pharmacogenetics and clinical psychopharmacology. He has organized several national and international workshops and Scientific conferences in Spain and Latin America. Currently he is Vicepresident of the Spanish Society of Pharmacogenetics and Pharmacogenomics and Vicepresident of the Spanish Society for Clinical Pharmacology. Since 2010 he is a member of the EMA Pharmacogenomics Working Parthy
University of Kiel, Germany
Full Professor of Pharmacology
Graduation in biochemistry and in medicine, Free University Berlin. Dr. rer. nat. (PhD) in 1989, specialization in clinical pharmacology at Charité Berlin (1998), Dr. med. (MD) in 1999. Habilitation in Clinical Pharmacology 2000, Professor of Pharmacology and Toxicology, University of Greifswald (2000-2004). Since 2004 Professor of Pharmacology and Director Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein. Since 2012 Dean of Education, Medical Faculty. Research is focused on pharmacogenomics and -epigenomics of drug metabolizing enzymes and transporters, mechanisms of drug resistance, drug-drug interactions as well as neuropathic pain research. Activity on various editorial boards, learned societies and advisory boards.
Member: AACR, AGAH, ASCPT, BPS (Fellow), DGK, DGKliPha (Chairman), DIVI, ESPT (Executive Board), IUPHAR (President)
Since 2014, he has been a member of the European Pediatric Group of Blood and Marrow Transplantation and chair of the clinical trial committee as well as board member of the European Society of Pharmacogenomics and Individualized Therapy, chair of the scientific division. In 2016, he created and became Head of the Swiss Group of Pharmacogenomics and Individualized Therapy.
Prof. Marc Ansari has practiced in the medical field for over 19 years, particularly in the areas of pediatric oncology-hematology and pharmacogenetics, in Geneva and in Montreal. In 2011 he created the first pediatric hematology and oncology research platform of the Faculty of Medicine in Geneva and founded the same year the CANSEARCH Foundation in order to support its activities. Since January 2013, he is Head of the Pediatric Onco-Hematology Unit of the Geneva University Hospital (HUG). In November 2015, he was appointed Professor Assistant at the Faculty of Medicine of Geneva, and, in October 2018, Professor Associate.
Member: Swiss Association of Medical Assistants and Heads of Clinics, Swiss Society of Pediatrics, American Society of Hematology, International Society of Pediatric Oncology, Swiss Society of Pediatric Oncology, French Society of Childhood Tumors, French Society of Transplantation, Swiss Medical Association, Swiss Hemophilia Network, Swiss Blood Stem Cells, Children’s Cancer and Leukemia Group, German Pediatric Oncology Group.
Board Member: Pediatric Disease Working Group of European Blood and Marrow, European Society of Pharmacogenomics and Individualized Therapy, Swiss Society of Toxicology and Clinical Pharmacology, Swiss Group of Pharmacogenomics and Individualized Therapy (Founder and Director), DNA germline SPOG Working group (chairman), Children’s Hepatic tumors International Collaboration (CHIC-SIOPEL).
General Secretary
Summary to be provided